AS

Archana Singh

Active Director Director DIN 03637277
DIN 03637277 First appointment Oct 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2011
Shareholding value •••• Premium profile

About Archana Singh

Data last updated:

Archana Singh is a Director at Balaark Pharmaceuticals Private Limited (since 2011). The company operates in Pharma. Balaark Pharmaceuticals Private Limited reported revenue of ₹2.70 Cr (FY 2025).

DIN 03637277
Primary Designation Director
Industry Pharma
First Appointment 17 Oct 2011
Oldest Company Age 15 yrs
Largest company Balaark Pharmaceuticals Private Limited · ₹2.70 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director17 Oct 20112011₹2.70 Cr (FY 2025)Active

Board colleagues of Archana Singh

Directorship timeline

Open interactive timeline →
Balaark Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Archana Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Archana Singh

Archana Singh currently holds 1 directorship: Balaark Pharmaceuticals Private Limited (Director, since 17 Oct 2011, revenue ₹2.70 Cr (FY 2025)).

Archana Singh was first appointed on 17 Oct 2011 as Director at Balaark Pharmaceuticals Private Limited.

The current boards of Archana Singh's companies include Anil Arora (Balaark Pharmaceuticals Private Limited), Neelam Singh (Balaark Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available